KULT Technology Spółka z Ograniczoną Odpowiedzialnością (KRS 0001215313, NIP 9662216100) is a Polish company, headquartered in Białystok, Podlaskie voivodeship. KULT TECHNOLOGY operates in: Scientific research and development (PKD 72.10.Z). Industry: Research and development. The company has been listed in the National Court Register since January 5, 2026.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - KULT Technology
Identity
- Name
- KULT Technology Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- January 5, 2026
- Registry status as of
- January 9, 2026
- Latest entry
- January 8, 2026
- Founding act
- 02.01.2026 R.
Articles of association history (1)
- January 2, 2026: 02.01.2026 R.
Activities
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- UL. JÓZEFA IGNACEGO KRASZEWSKIEGO, 30, 23, 15-025, BIAŁYSTOK, POLSKA
- Voivodeship
- PODLASKIE
- District
- BIAŁYSTOK
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- Not disclosed in the registry
- Coordinates
- 53.1322, 23.1588approx.
Operational status - KULT Technology
Founded
January 5, 2026
0 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
BIAŁYSTOK
PODLASKIE
Primary PKD
72.10.Z
Scientific research and development
Share capital
5.1 K PLN
51 shares total
Shareholders
3
shareholders
Board
2 people
Filed years
N/A
Registry entries
3
latest: January 8, 2026
No KPI data - financial statements and valuation are unavailable for this company.
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - KULT Technology.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
